Japan-based pharmaceutical company Astellas Pharma announced its plans to foray into the Indian market and establish its business in the country by developing sales and marketing infrastructure for its products base.
"We have a long-term commitment to India and our focus will be to deliver innovative and reliable pharmaceutical products for improving the health of the people. With this beginning, we hope to succeed in long-term growth," Astellas Pharma India Managing Director Teruo Yasufuku told pharmaquest.biz.
The company plans to introduce its flagship product, Prograf first, which is used after organ transplantation, Yasufuku said.
India is one of the fastest-growing pharmaceutical markets in the world. Driven by huge patient base, increasing incomes and strong penetration of health insurance, the pharma market is expected to more than double its size in the next five years, Astellas Pharma India Director-Sales & Marketing Himanshu Dave said.
Astellas Pharma Inc is a global category leader in transplantation and urology segment.